Targeting IL-1β in disease; the expanding role of NLRP3 inflammasome

European Journal of Internal Medicine

Volumn 21, Issue 3, 2010, Pages 157-163

  Mitroulis, Ioannis ^a   Skendros, Panagiotis ^a   Ritis, Konstantinos ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Anakinra; Autoinflammatory syndromes; Canakinumab; IL 1 ; Rilonacept

Indexed keywords

ANTIINFLAMMATORY AGENT; CANAKINUMAB; COLCHICINE; CRYOPYRIN; ETANERCEPT; INFLAMMASOME; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME INHIBITOR; METFORMIN; PRALNACASAN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; RITUXIMAB; TOCILIZUMAB; UNCLASSIFIED DRUG; VX 765; ANTIRHEUMATIC AGENT; CARRIER PROTEIN; NLRP3 PROTEIN, HUMAN;

ACUTE HEPATITIS; ADULT ONSET STILL DISEASE; ANTIINFLAMMATORY ACTIVITY; AUTOINFLAMMATORY DISEASE; CHICKENPOX; CINCA SYNDROME; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; FAMILIAL MEDITERRANEAN FEVER; GENETIC DISORDER; GOUT; HERPES SIMPLEX; HUMAN; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; IMMUNOREGULATION; INFECTION; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE RHEUMATOID ARTHRITIS; LEISHMANIASIS; LOADING DRUG DOSE; MUCKLE WELLS SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOARTHRITIS; PROTEIN FUNCTION; PROTEIN TARGETING; PSEUDOGOUT; PSORIASIS; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; SHORT SURVEY; UPPER RESPIRATORY TRACT INFECTION; AUTOIMMUNE DISEASE; DRUG ANTAGONISM; IMMUNOLOGY; INFLAMMATION; REVIEW;

ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; AUTOIMMUNE DISEASES; CARRIER PROTEINS; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA;

EID: 77952287367     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2010.03.005     Document Type: Short Survey

References (85)

1. Franchi L., Warner N., Viani K., and Nuñez G. Function of Nod-like receptors in microbial recognition and host defense. Immunol Rev 227 (2009) 106-128
2. Martinon F., Mayor A., and Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 27 (2009) 229-265
3. Masters L.S., Simon A., Aksentijevich I., and Kastner D.L. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 27 (2009) 621-668
4. Agostini L., Martinon F., Burns K., McDermott M.F., Hawkins P.N., and Tschopp J. NALP3 forms an Il-l beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 20 (2004) 319-325
5. Hoffman H.M., Mueller J.L., Broide D.H., Wanderer A.A., and Kolodner R.D. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 29 (2001) 301-305
6. Aksentijevich I., Nowak M., Mallah M., Chae J.J., Watford W.T., Hofmann S.R., et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 46 (2002) 3340-3348
7. The international FMF consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 90 (1997) 797-807
8. Chae J.J., Komarow H.D., Cheng J., Wood G., Raben N., Liu P.P., et al. Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol Cell 11 (2003) 591-604
9. Chae J.J., Wood G., Masters S.L., Richard K., Park G., Smith B.J., et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1β production. Proc Natl Acad Sci USA 103 (2006) 9982-9987
10. Shoham N.G., Centola M., Mansfield E., Hull K.M., Wood G., Wise C.A., et al. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci USA 100 (2003) 13501-13506
11. Martinon F., Petrilli V., Mayor A., Tardivel A., and Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440 (2006) 237-241
12. Chen C.J., Shi Y., Hearn A., Fitzgerald K., Golenbock D., Reed G., et al. MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest 116 (2006) 2262-2271
13. Halle A., Hornung V., Petzold G.C., Stewart C.R., Monks B.G., Reinheckel T., et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 9 (2008) 857-865
14. Dostert C., Pétrilli V., Van Bruggen R., Steele C., Mossman B.T., and Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320 (2008) 674-677
15. Schroder K., Zhou R., and Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger?. Science 327 (2010) 296-300
16. Zhou R., Tardivel A., Thorens B., Choi I., and Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 11 (2010) 136-140
17. Reddy S., Jia S., Geoffrey R., Lorier R., Suchi M., Broeckel U., et al. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N Engl J Med 360 (2009) 2438-2444
18. Aksentijevich I., Masters S.L., Ferguson P.J., Dancey P., Frenkel J., van Royen-Kerkhoff A., et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 360 (2009) 2426-2437
19. Pascual V., Allantaz F., Arce E., Punaro M., and Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 201 (2005) 1479-1486
20. Gattorno M., Piccini A., Lasigliè D., Tassi S., Brisca G., Carta S., et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 58 (2008) 1505-1515
21. Kahle P., Saal J.G., Schaudt K., Zacher J., Fritz P., and Pawelec G. Determination of cytokines in synovial fluids: correlation with diagnosis and histomorphological characteristics of synovial tissue. Ann Rheum Dis 51 (1992) 731-734
22. Kolly L., Busso N., Palmer G., Talabot-Ayer D., Chobaz V., and So A. Expression and function of the NALP3 inflammasome in rheumatoid synovium. Immunology 2 (2010) 178-185
23. Kastbom A., Verma D., Eriksson P., Skogh T., Wingren G., and Söderkvist P. Genetic variation in proteins of the cryopyrin inflammasome influences susceptibility and severity of rheumatoid arthritis (the Swedish TIRA project). Rheumatology (Oxford) 47 (2008) 415-417
24. Cho J.H. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol 8 (2008) 458-466
25. Miceli-Richard C., Lesage S., Rybojad M., Prieur A.M., Manouvrier-Hanu S., Hafner R., et al. CARD15 mutations in Blau syndrome. Nat Gen 29 (2001) 19-20
26. Fritz J.H., Ferrero R.L., Philpott D.J., and Girardin S.E. Nod-like proteins in immunity, inflammation and disease. Nat immunol 7 (2006) 1250-1257
27. Martin T.M., Zhang Z., Kurz P., Rosé C.D., Chen H., Lu H., et al. The NOD2 defect in Blau syndrome does not result in excess interleukin-1 activity. Arthritis Rheum 60 (2009) 611-618
28. Travassos L.H., Carneiro L.A., Ramjeet M., Hussey S., Kim Y.G., Magalhães J.G., et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol 11 (2010) 55-62
29. Cooney R., Baker J., Brain O., Danis B., Pichulik T., Allan P., et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med 16 (2010) 90-97
30. Saitoh T., Fujita N., Jang M.H., Uematsu S., Yang B.G., Satoh T., et al. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature 456 (2008) 264-268
31. Stojanov S., Hoffmann F., Kery A., Renner E.D., Hartl D., Lohse P., et al. Cytokine profile in PFAPA syndrome suggests continuous inflammation and reduced anti-inflammatory response. Eur Cytokine Netw 17 (2006) 90-97
32. Dinarello C.A. The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med 343 (2000) 732-734
33. Lequerré T., Quartier P., Rosellini D., Alaoui F., De Bandt M., Mejjad O., et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 67 (2008) 302-308
34. Canna S., Frankovich J., Higgins G., Narkewicz M.R., Nash S.R., Hollister J.R., et al. Acute hepatitis in three patients with systemic juvenile idiopathic arthritis taking interleukin-1 receptor antagonist. Pediatr Rheumatol Online J 7 (2009) 21
35. Economides A.N., Carpenter L.R., Rudge J.S., Wong V., Koehler-Stec E.M., Hartnett C., et al. Cytokine traps: multi-component, high affinity blockers of cytokine action. Nat Med 9 (2003) 47-52
36. Goldbach-Mansky R., Shroff S.D., Wilson M., Snyder C., Plehn S., Barham B., et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum 58 (2008) 2432-2442
37. Hoffman H.M., Throne M.L., Amar N.J., Sebai M., Kivitz A.J., Kavanaugh A., et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 58 (2008) 2443-2452
38. Church L.D., and McDermott M.F. Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders. Curr Opin Mol Ther 11 (2009) 81-89
39. Lachmann H.J., Kone-Paut I., Kuemmerle-Deschner J.B., Leslie K.S., Hachulla E., Quartier P., et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 360 (2009) 2416-2425
40. Hoffman H.M., Rosengren S., Boyle D.L., Cho J.Y., Nayar J., Mueller J.L., et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364 (2004) 1779-1785
41. Maksimovic L., Stirnemann J., Caux F., Ravet N., Rouaghe S., Cuisset L., et al. New CIAS1 mutation and anakinra efficacy in overlapping of Muckle-Wells and familial cold autoinflammatory syndromes. Rheumatology (Oxford) 47 (2008) 309-310
42. Goldbach-Mansky R., Dailey N.J., Canna S.W., Gelabert A., Jones J., Rubin B.I., et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 355 (2006) 581-592
43. Yamazaki T., Masumoto J., Agematsu K., Sawai N., Kobayashi S., Shigemura T., et al. Anakinra improves sensory deafness in a Japanese patient with Muckle-Wells syndrome, possibly by inhibiting the cryopyrin inflammasome. Arthritis Rheum 58 (2008) 864-868
44. Leslie K.S., Lachmann H.J., Bruning E., McGrath J.A., Bybee A., Gallimore J.R., et al. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol 142 (2006) 1591-1597
45. Thornton B.D., Hoffman H.M., Bhat A., and Don B.R. Successful treatment of renal amyloidosis due to familial cold autoinflammatory syndrome using an interleukin 1 receptor antagonist. Am J Kidney Dis 49 (2007) 477-481
46. Neven B., Marvillet I., Terrada C., Ferster A., Boddaert N., Couloignier V., et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum 62 (2009) 258-267
47. Hashkes P.J., and Laxer R. Medical treatment of juvenile idiopathic arthritis. JAMA 294 (2005) 1671-1684
48. Zeft A., Hollister R., LaFleur B., Sampath P., Soep J., McNally B., et al. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience. J Clin Rheumatol 15 (2009) 161-164
49. Fitzgerald A.A., LeClercq S.A., Yan A., Homik J.E., and Dinarello C.A. Rapid responses to anakinra in patients with refractory adult onset Still's disease. Arthritis Rheum 52 (2005) 1794-1803
50. Verbsky J.W., and White A.J. Effective use of the recombinant interleukin receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 31 (2004) 2071-2075
51. Priori R., Ceccarelli F., Barone F., Iagnocco A., and Valesini G. Clinical, biological and sonographic response to IL-1 blockade in adult-onset Still's disease. Clin Exp Rheumatol 26 (2008) 933-937
52. Naumann L., Feist E., Natusch A., Langen S., Krause A., Buttgereit F., et al. IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease. Ann Rheum Dis 69 (2010) 466-467
53. Ilowite N., Porras O., Reiff A., Rudge S., Punaro M., Martin A., et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol 28 (2009) 129-137
54. Terkeltaub R.A. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol 6 (2010) 30-38
55. So A., De Smedt T., Revaz S., and Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 9 (2007) R28
56. McGonagle D., Tan A.L., Shankaranarayana S., Madden J., Emery P., and McDermott M.F. Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann Rheum Dis 66 (2007) 1683-1684
57. Gratton S.B., Scalapino K.J., and Fye K.H. Case of anakinra as a steroid-sparing agent for gout inflammation. Arthritis Rheum 61 (2009) 1268-1270
58. Terkeltaub R., Sundy J.S., Schumacher H.R., Murphy F., Bookbinder S., Biedermann S., et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 68 (2009) 1613-1617
59. Announ N., Palmer G., Guerne P.A., and Gabay C. Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure. Joint Bone Spine 76 (2009) 424-426
60. Papadopoulos V.P., Giaglis S., Mitroulis I., and Ritis K. The population genetics of familial mediterranean fever: a meta-analysis study. Ann Hum Genet 72 (2008) 752-761
61. Calligaris L., Marchetti F., Tommasini A., and Ventura A. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur J Pediatr 167 (2008) 695-696
62. Gattringer R., Lagler H., Gattringer K.B., Knapp S., Burgmann H., Winkler S., et al. Anakinra in two adolescent female patients suffering from colchicine-resistant familial Mediterranean fever: effective but risky. Eur J Clin Invest 37 (2007) 912-914
63. Kuijk L.M., Govers A.M., Frenkel J., and Hofhuis W.J. Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra. Ann Rheum Dis 66 (2007) 1545-1546
64. Moser C., Pohl G., Haslinger I., Knapp S., Rowczenio D., Russel T., et al. Successful treatment of familial Mediterranean fever with anakinra and outcome after renal transplantation. Nephrol Dial Transplant 24 (2009) 676-678
65. Mitroulis I., Papadopoulos V.P., Konstantinidis T., and Ritis K. Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patient. Neth J Med 66 (2008) 489-491
66. Bilginer Y., Ayaz N.A., and Ozen S. Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet's disease. Clin Rheumatol 29 (2010) 209-210
67. Gartlehner G., Hansen R.A., Jonas B.L., Thieda P., and Lohr K.N. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 33 (2006) 2398-2408
68. Genovese M.C., Cohen S., Moreland L., Lium D., Robbins S., Newmark R., et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 50 (2004) 1412-1419
69. Larsen C.M., Faulenbach M., Vaag A., Vølund A., Ehses J.A., Seifert B., et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356 (2007) 1517-1526
70. Larsen C.M., Faulenbach M., Vaag A., Ehses J.A., Donath M.Y., and Mandrup-Poulsen T. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 32 (2009) 1663-1668
71. Bodar E.J., van der Hilst J.C., Drenth J.P., van der Meer J.W., and Simon A. Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. Neth J Med 63 (2005) 260-264
72. Rigante D., Ansuini V., Bertoni B., Pugliese A.L., Avallone L., Federico G., et al. Treatment with anakinra in the hyperimmunoglobulinemia D/periodic fever syndrome. Rheumatol Int 27 (2006) 97-100
73. Dybowski F., Sepp N., Bergerhausen H.J., and Braun J. Successful use of anakinra to treat refractory Schnitzler's syndrome. Clin Exp Rheumatol 26 (2008) 354-357
74. Frischmeyer-Guerrerio P.A., Rachamalla R., and Saini S.S. Remission of Schnitzler syndrome after treatment with anakinra. Ann Allergy Asthma Immunol 100 (2008) 617-619
75. Gilson M., Abad S., Larroche C., and Dhote R. Treatment of Schnitzler's syndrome with anakinra. Clin Exp Rheumatol 25 (2007) 931
76. Besada E., and Nossent H. Dramatic response to IL1-RA treatment in longstanding multidrug resistant Schnitzler's syndrome: a case report and literature review. Clin Rheumatol (2010) 10.1007/s10067-010-1375-9 [Electronic publication ahead of print]
77. Botsios C., Sfriso P., Furlan A., Punzi L., and Dinarello C.A. Resistant Behçet disease responsive to anakinra. Ann Intern Med 149 (2008) 284-286
78. Brenner M., Ruzicka T., Plewig G., Thomas P., and Herzer P. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol 161 (2009) 1199-1201
79. Dierselhuis M.P., Frenkel J., Wulffraat N.M., and Boelens J.J. Anakinra for flares of pyogenic arthritis in PAPA syndrome. Rheumatology (Oxford) 44 (2005) 406-408
80. Gattorno M., Pelagatti M.A., Meini A., Obici L., Barcellona R., Federici S., et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 58 (2008) 1516-1520
81. Simon A., Bodar E.J., van der Hilst J.C., van der Meer J.W., Fiselier T.J., Cuppen M.P., et al. Beneficial response to interleukin 1 receptor antagonist in traps. Am J Med 117 (2004) 208-210
82. Bodar E.J., Simon A., de Visser M., and van der Meer J.W. Complete remission of severe idiopathic cold urticaria on interleukin-1 receptor antagonist (anakinra). Neth J Med 67 (2009) 302-305
83. Picco P., Brisca G., Traverso F., Loy A., Gattorno M., and Martini A. Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): an unrecognized autoinflammatory disease?. Arthritis Rheum 60 (2009) 264-268
84. Cornelis S., Kersse K., Festjens N., Lamkanfi M., and Vandenabeele P. Inflammatory caspases: targets for novel therapies. Curr Pharm Des 13 (2007) 367-385
85. Stack J.H., Beaumont K., Larsen P.D., Straley K.S., Henkel G.W., Randle J.C., et al. IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients. J Immunol 175 (2005) 2630-2634